{"id":868,"date":"2022-04-26T17:06:16","date_gmt":"2022-04-26T22:06:16","guid":{"rendered":"https:\/\/nuvaira.com\/clinical-evidence\/"},"modified":"2022-06-02T08:39:00","modified_gmt":"2022-06-02T13:39:00","slug":"clinical-evidence","status":"publish","type":"page","link":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/","title":{"rendered":"Preuves cliniques"},"content":{"rendered":"<div class=\"nuvairaBlock context-purple\">\n    <div class=\"pageHeroBlok\">\n        <div class=\"container\">\n\n            <h1 class=\"pageHeroBlok__title\">Preuves cliniques<\/h1>\n                            <div class=\"pageHeroBlok__description | wysiwyg\">\n                    <p>L\u2019ensemble des r\u00e9sultats de notre programme de d\u00e9veloppement clinique a d\u00e9montr\u00e9 la s\u00e9curit\u00e9 et l\u2019impact de la D\u00e9nervation Cibl\u00e9e des Poumons (DCP) utilisant le syst\u00e8me de d\u00e9nervation des poumons dNerva\u00ae. Des informations d\u00e9taill\u00e9es sur les \u00e9tudes cliniques de Nuvaira sont disponibles sur <a href=\"https:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/a>.<\/p>\n<p><strong>Notre essai AIRFLOW-3 est en cours de recrutement !<\/strong><\/p>\n                <\/div>\n            \n                        \n            \n            \n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-white context-white\">\n<div class=\"container\">\n\n            <h2 class=\"text-center mb-56 h-4\">dNerva\u00ae Programme de d\u00e9veloppement clinique<\/h2>\n    \n    <div class=\"clinicalDevBlok \">\n        \n\n            <div class=\"clinicalDevBlok__item\">\n                <div class=\"clinicalDevBlok__image\">\n                    <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"75\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-1-300x75.png\" class=\"attachment-medium size-medium\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-1-300x75.png 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-1.png 352w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>                <\/div>\n\n                                    <h3 class=\"clinicalDevBlok__title\"> Phase 1A (Preuve de concept \/ D\u00e9termination de dose) <\/h3>\n                \n                \n                                    <ul class=\"clinicalDevBlok__list\">\n                                                    <li>N=37<\/li>\n                                                    <li>\r\nBras unique<\/li>\n                                                    <li>\r\nD\u00e9termination de dose<\/li>\n                                                    <li>\r\nPreuve de concept<\/li>\n                                            <\/ul>\n                \n                                    <div class=\"clinicalDevBlok__more\">\n                        Donn\u00e9es \u00e0 3 ans : <sup>25<\/sup>                    <\/div>\n                \n            <\/div>\n        \n\n            <div class=\"clinicalDevBlok__item\">\n                <div class=\"clinicalDevBlok__image\">\n                    <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"113\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-2A-300x113.png\" class=\"attachment-medium size-medium\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-2A-300x113.png 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-2A.png 334w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>                <\/div>\n\n                                    <h3 class=\"clinicalDevBlok__title\"> Phase 2A (S\u00e9curit\u00e9 \/ D\u00e9termination de dose) <\/h3>\n                \n                \n                                    <ul class=\"clinicalDevBlok__list\">\n                                                    <li>N=46<\/li>\n                                                    <li>\r\nBras unique <\/li>\n                                                    <li>\r\nD\u00e9termination de dose<\/li>\n                                                    <li>\r\nS\u00e9curit\u00e9<\/li>\n                                            <\/ul>\n                \n                                    <div class=\"clinicalDevBlok__more\">\n                        Donn\u00e9es \u00e0 1 an : <sup>27<\/sup><br \/>\r\nDonn\u00e9es \u00e0 3 ans : <sup>21<\/sup><br \/>\r\n                    <\/div>\n                \n            <\/div>\n        \n\n            <div class=\"clinicalDevBlok__item\">\n                <div class=\"clinicalDevBlok__image\">\n                    <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"109\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-2B-300x109.png\" class=\"attachment-medium size-medium\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-2B-300x109.png 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-2B.png 334w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>                <\/div>\n\n                                    <h3 class=\"clinicalDevBlok__title\"> Phase 2B (S\u00e9curit\u00e9 \/ Faisabilit\u00e9) <\/h3>\n                \n                \n                                    <ul class=\"clinicalDevBlok__list\">\n                                                    <li>N=82<\/li>\n                                                    <li>\r\nS\u00e9curit\u00e9 et faisabilit\u00e9<\/li>\n                                                    <li>\r\nRandomis\u00e9e 1:1 contre proc\u00e9dure simul\u00e9e<\/li>\n                                                    <li>\r\nDouble aveugle (1 an)<\/li>\n                                                    <li>\r\nCrossover<\/li>\n                                                    <li>\r\nEurope<\/li>\n                                            <\/ul>\n                \n                                    <div class=\"clinicalDevBlok__more\">\n                        Donn\u00e9es \u00e0 1 an : <sup>26<\/sup><br \/>\r\nDonn\u00e9es \u00e0 2 ans : <sup>2<\/sup>                    <\/div>\n                \n            <\/div>\n        \n\n            <div class=\"clinicalDevBlok__item\">\n                <div class=\"clinicalDevBlok__image\">\n                    <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"109\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-3-300x109.png\" class=\"attachment-medium size-medium\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-3-300x109.png 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/phase-3.png 335w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>                <\/div>\n\n                                    <h3 class=\"clinicalDevBlok__title\"> Phase 3 (Etude Pivot) <\/h3>\n                \n                \n                                    <ul class=\"clinicalDevBlok__list\">\n                                                    <li>N=plus de 400<\/li>\n                                                    <li>\r\nS\u00e9curit\u00e9 et faisabilit\u00e9<\/li>\n                                                    <li>\r\nRandomis\u00e9e 1:1 contre proc\u00e9dure simul\u00e9e<\/li>\n                                                    <li>\r\nDouble aveugle (1 an)<\/li>\n                                                    <li>\r\nCrossover<\/li>\n                                                    <li>\r\nUSA et Europe<\/li>\n                                            <\/ul>\n                \n                                    <div class=\"clinicalDevBlok__more\">\n                        Etude en cours de recrutement                    <\/div>\n                \n            <\/div>\n        \n        \n        \n        \n        \n        \n    <\/div>\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-gray context-gray --previous-regular\">\n    <div class=\"container\">\n        <div class=\"sectionHeading sectionHeading--no-ornament  sectionHeading--center\">\n\n            <div class=\"sectionHeading__content\">\n\n                \n                                    <h2 class=\"h-2\">Etudes<\/h2>\n                \n                                    <p class=\"mt-32\">\n                        Retrouvez ci-dessous les informations sur le programme de d\u00e9veloppement clinique de Nuvaira.                    <\/p>\n                \n            <\/div>\n\n            \n        <\/div>\n    <\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-gray context-gray --previous-regular\">\n<div class=\"container\">\n    <div class=\"contentSidebarBlok\">\n\n                    <div class=\"contentSidebarBlok__image | mb-32\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"550\" height=\"199\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-2.png\" class=\"attachment-medium_large size-medium_large\" alt=\"Clinical Development Program AIRFLOW-2\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-2.png 550w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-2-300x109.png 300w\" sizes=\"auto, (max-width: 550px) 100vw, 550px\" \/>            <\/div>\n                \n                    <h3 class=\"h-4 mb-24\">Pr\u00e9sentation de l\u2019\u00e9tude<\/h3>\n        \n        <div class=\"contentSidebarBlok__layout\">\n            <div class=\"contentSidebarBlok__main wysiwyg\">\n                <p>AIRFLOW-2 \u00e9tait un essai clinique multicentrique, randomis\u00e9, en double aveugle, contr\u00f4l\u00e9 par un traitement simul\u00e9, visant \u00e0 \u00e9valuer les \u00e9v\u00e9nements ind\u00e9sirables d\u2019origine respiratoire chez 82 patients atteints de BPCO mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re, tr\u00e8s symptomatiques malgr\u00e9 un traitement pharmaceutique optimal. <strong>Les r\u00e9sultats de notre essai clinique AIRFLOW-2 confirment la s\u00e9curit\u00e9 de l\u2019intervention et fournissent une solide base clinique et \u00e9conomique pour l\u2019essai pivot AIRFLOW-3. <\/strong><\/p>\n            <\/div>\n\n            <div class=\"contentSidebarBlok__aside contentSidebarBlok__aside--featured\">\n                                \n                                            <div class=\"contentSidebarBlok__firstLine\">R\u00e9sultats : Impact sur les r\u00e9sultats \u00e0 deux ans<sup>2<\/sup><\/div>\n                                                                <div class=\"contentSidebarBlok__secondLine mt-8\">Diminution de 62% du risque d\u2019exacerbation s\u00e9v\u00e8re<\/div>\n                                                                <div class=\"contentSidebarBlok__thirdLine mt-8\">chez les patients atteints de BPCO trait\u00e9s par D\u00e9nervation Cibl\u00e9e des Poumons<\/div>\n                    \n                            <\/div>\n        <\/div>\n\n\n\n    <\/div>\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-gray context-gray --previous-regular\"><div class=\"container\">\n    <div class=\"excerptCardBlok context-white\">\n\n        <div class=\"excerptCardBlok__container text-center\">\n\n                            <div class=\"excerptCardBlok__title\"><p>Publi\u00e9 dans la revue <em>International Journal of Chronic Obstructive Pulmonary Disease<\/em>, novembre 2020<sup>2<\/sup><\/p>\n<\/div>\n            \n                            <div class=\"excerptCardBlok__content\">\n                    <p>\u00ab L\u2019impact clinique de la DCP est durable, car elle r\u00e9duit le risque d\u2019\u00e9v\u00e9nements ind\u00e9sirables graves li\u00e9s \u00e0 la BPCO sur une p\u00e9riode de deux ans, tout en stabilisant la fonction pulmonaire. La r\u00e9duction des exacerbations s\u00e9v\u00e8res de la BPCO peut potentiellement am\u00e9liorer les r\u00e9sultats cliniques \u00e0 long terme et r\u00e9duire ainsi les co\u00fbts de soins de sant\u00e9. \u00bb<\/p>\n                <\/div>\n            \n                            <div class=\"mt-16\">\n                        <a class=\"btn btn--link\" href=\"https:\/\/www.dovepress.com\/two-year-outcomes-for-the-double-blind-randomized-sham-controlled-stud-peer-reviewed-fulltext-article-COPD\" target=\"_blank\">\n        Consultez le rapport complet <i class=\"far fa-arrow-right\"><\/i>\n    <\/a>\n                    <\/div>\n            \n\n        <\/div>\n\n    <\/div>\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-gray context-gray --previous-regular\"><div class=\"container\">\n            <h3 class=\"h-4 | mb-32\">Conclusions de l\u2019\u00e9tude AIRFLOW-2<\/h3>\n        <div class=\"iconGridBlok iconGridBlok--small iconGridBlok--4cols\">\n\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-books\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>M\u00e9thodologie robuste<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-shield-check\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Profil de s\u00e9curit\u00e9 favorable<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-chart-line-down\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Significativement moins de risque d\u2019hospitalisation pour exacerbation de la BPCO<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-lungs\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>La fonction pulmonaire et la qualit\u00e9 de vie sont rest\u00e9es stables pendant 2 ans <\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n        \n    <\/div>\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n\n<div class=\"horizontal-line\">\n    <hr \/>\n<\/div>\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-small --space-bot-regular --bg-gray context-gray --previous-regular\">\n<div class=\"container\">\n    \n    <div class=\"collapsableGridBlok\">\n        \n        <h3 class=\"collapsableGridBlok__title | h-4\">\n            D\u00e9tails de l\u2019\u00e9tude AIRFLOW-2         <\/h3>\n\n        <div class=\"collapsableGridBlok__content\">\n\n            <div class=\"collapsableGridBlok__layout\">\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Design de l\u2019\u00e9tude<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Evaluer la s\u00e9curit\u00e9 et l\u2019impact de la D\u00e9nervation Cibl\u00e9e des Poumons sur les exacerbations mod\u00e9r\u00e9es \u00e0 s\u00e9v\u00e8res, chez les patients BPCO symptomatiques sous traitement m\u00e9dicamenteux optimal <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Population<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Patients diagnostiqu\u00e9s BPCO, exacerbations mod\u00e9r\u00e9es \u00e0 s\u00e9v\u00e8res, symptomatiques et \u00e0 risque d\u2019exacerbation de BPCO (GOLD 2\/3, Groupe D) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Investigateurs principaux<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Arschang Valipour, MD, Otto-Wagner Spital (Vienna, Austria)<br \/>\r\nDirk-Jan Slebos, MD, Ph.D., UMCG (Groningen Netherlands) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Crit\u00e8re d\u2019\u00e9valuation principal<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Diff\u00e9rence de fr\u00e9quence (pourcentage) des \u00e9v\u00e9nements ind\u00e9sirables pr\u00e9d\u00e9finis d\u2019origine respiratoire entre 3 et 6,5 mois apr\u00e8s l\u2019intervention, entre le groupe de traitement par DCP et le groupe contr\u00f4le (proc\u00e9dure simul\u00e9e &#8211; sham) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Nombre\/Centres\t<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> N=82 (Randomisation 1:1)<br \/>\r\nMulticentrique Europe<br \/>\r\n <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Suivi<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> 0-12,5 mois (jusqu\u2019\u00e0 la lev\u00e9e de l\u2019aveugle)<br \/>\r\nSuivi annuel pendant 5 ans  <\/p>\n                    <\/div>\n                            <\/div>\n\n        <\/div>\n\n        \n    <\/div>\n\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-white context-white --previous-regular\">\n<div class=\"container\">\n    <div class=\"contentSidebarBlok\">\n\n                    <div class=\"contentSidebarBlok__image | mb-32\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"550\" height=\"206\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-1.png\" class=\"attachment-medium_large size-medium_large\" alt=\"Nuvaira Clinical Development Program AIRFLOW-1\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-1.png 550w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-1-300x112.png 300w\" sizes=\"auto, (max-width: 550px) 100vw, 550px\" \/>            <\/div>\n                \n                    <h3 class=\"h-4 mb-24\">Pr\u00e9sentation de l\u2019\u00e9tude<\/h3>\n        \n        <div class=\"contentSidebarBlok__layout\">\n            <div class=\"contentSidebarBlok__main wysiwyg\">\n                <p>AIRFLOW-1 \u00e9tait une \u00e9tude multicentrique portant sur la s\u00e9curit\u00e9 et la d\u00e9termination de dose de la DCP chez les patients atteints de BPCO mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re. <strong>Les r\u00e9sultats de notre essai clinique AIRFLOW-1 indiquent que la fonction pulmonaire des patients est rest\u00e9e stable jusqu\u2019\u00e0 3 ans apr\u00e8s le traitement et que le taux annuel de d\u00e9gradation du VEMS a diminu\u00e9 apr\u00e8s le traitement<sup>21,22<\/sup>.<\/strong><\/p>\n            <\/div>\n\n            <div class=\"contentSidebarBlok__aside contentSidebarBlok__aside--bubbles\">\n                \n                    <div class=\"c-purple\">\n                        <div class=\"logoDots\">\n    <svg width=\"276\" height=\"128\" viewBox=\"0 0 276 128\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n        <path class=\"path-0\" d=\"M207.1 29.4507C207.1 32.2756 206.262 35.037 204.693 37.3858C203.123 39.7346 200.893 41.5652 198.283 42.6462C195.673 43.7273 192.801 44.0101 190.031 43.459C187.26 42.9079 184.715 41.5476 182.718 39.5501C180.72 37.5526 179.36 35.0077 178.809 32.2371C178.258 29.4665 178.541 26.5948 179.622 23.9849C180.703 21.3751 182.533 19.1445 184.882 17.575C187.231 16.0056 189.992 15.168 192.817 15.168C196.605 15.168 200.238 16.6728 202.917 19.3513C205.595 22.0298 207.1 25.6627 207.1 29.4507Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-1\" d=\"M187.732 76.212C187.738 78.2019 187.153 80.1488 186.051 81.8061C184.95 83.4634 183.381 84.7566 181.545 85.522C179.708 86.2874 177.685 86.4907 175.733 86.1059C173.78 85.7212 171.986 84.7658 170.577 83.3607C169.168 81.9556 168.207 80.164 167.817 78.2128C167.427 76.2615 167.624 74.2383 168.384 72.3993C169.145 70.5603 170.433 68.9883 172.088 67.8821C173.742 66.776 175.687 66.1856 177.677 66.1855C180.339 66.1855 182.892 67.241 184.777 69.1205C186.662 71 187.724 73.5502 187.732 76.212Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-2\" d=\"M241.265 49.1612C241.27 51.1511 240.685 53.098 239.584 54.7553C238.483 56.4126 236.914 57.7058 235.077 58.4712C233.24 59.2367 231.218 59.4399 229.266 59.0551C227.313 58.6704 225.519 57.715 224.11 56.3099C222.701 54.9048 221.74 53.1132 221.35 51.162C220.96 49.2107 221.157 47.1875 221.917 45.3485C222.677 43.5096 223.966 41.9375 225.62 40.8313C227.274 39.7252 229.22 39.1348 231.21 39.1348C233.871 39.1348 236.425 40.1902 238.309 42.0697C240.194 43.9492 241.257 46.4994 241.265 49.1612Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-3\" d=\"M174.107 112.177C174.107 113.555 173.698 114.903 172.932 116.049C172.166 117.195 171.077 118.088 169.804 118.616C168.53 119.143 167.129 119.281 165.777 119.013C164.425 118.744 163.183 118.08 162.208 117.105C161.233 116.13 160.569 114.888 160.3 113.536C160.032 112.184 160.17 110.783 160.697 109.509C161.225 108.236 162.118 107.147 163.264 106.381C164.41 105.615 165.758 105.207 167.137 105.207C168.983 105.214 170.751 105.951 172.057 107.256C173.362 108.562 174.099 110.33 174.107 112.177Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-4\" d=\"M216.384 91.0369C216.384 92.4154 215.975 93.763 215.209 94.9092C214.443 96.0554 213.355 96.9487 212.081 97.4763C210.808 98.0038 209.406 98.1418 208.054 97.8729C206.702 97.604 205.46 96.9401 204.485 95.9654C203.511 94.9906 202.847 93.7487 202.578 92.3966C202.309 91.0446 202.447 89.6432 202.974 88.3696C203.502 87.096 204.395 86.0074 205.542 85.2415C206.688 84.4757 208.035 84.0669 209.414 84.0669C211.262 84.0669 213.035 84.8012 214.342 86.1083C215.65 87.4155 216.384 89.1883 216.384 91.0369Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-5\" d=\"M195.559 122.832C195.559 123.803 195.271 124.753 194.731 125.561C194.191 126.369 193.423 126.999 192.526 127.371C191.628 127.743 190.64 127.84 189.687 127.651C188.734 127.461 187.858 126.993 187.171 126.306C186.484 125.619 186.016 124.743 185.827 123.79C185.637 122.837 185.734 121.849 186.106 120.952C186.478 120.054 187.108 119.286 187.916 118.746C188.724 118.207 189.674 117.918 190.645 117.918C191.949 117.918 193.198 118.436 194.12 119.358C195.041 120.279 195.559 121.529 195.559 122.832Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-6\" d=\"M234.522 109.006C234.522 109.979 234.233 110.93 233.692 111.738C233.151 112.547 232.382 113.177 231.482 113.548C230.583 113.919 229.593 114.014 228.639 113.822C227.686 113.63 226.81 113.16 226.124 112.47C225.438 111.78 224.973 110.901 224.786 109.947C224.6 108.992 224.701 108.003 225.078 107.106C225.454 106.208 226.088 105.443 226.9 104.906C227.711 104.37 228.664 104.087 229.637 104.092C230.935 104.1 232.178 104.621 233.093 105.541C234.008 106.462 234.522 107.707 234.522 109.006Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-7\" d=\"M276 92.8093C276 93.781 275.712 94.7309 275.172 95.5389C274.632 96.3469 273.865 96.9766 272.967 97.3485C272.069 97.7204 271.082 97.8177 270.129 97.6281C269.176 97.4385 268.3 96.9706 267.613 96.2835C266.926 95.5963 266.458 94.7209 266.268 93.7678C266.079 92.8147 266.176 91.8268 266.548 90.929C266.92 90.0313 267.549 89.2639 268.357 88.724C269.165 88.1842 270.115 87.896 271.087 87.896C272.39 87.896 273.64 88.4136 274.561 89.3351C275.483 90.2565 276 91.5062 276 92.8093Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-8\" d=\"M262.175 71.4138C262.18 72.7992 261.775 74.1551 261.009 75.3098C260.243 76.4644 259.152 77.3659 257.874 77.9C256.596 78.434 255.188 78.5767 253.828 78.3099C252.469 78.0431 251.219 77.3788 250.237 76.4012C249.256 75.4236 248.586 74.1766 248.314 72.8183C248.042 71.4599 248.179 70.0513 248.707 68.7708C249.236 67.4903 250.133 66.3956 251.285 65.6253C252.436 64.855 253.791 64.4439 255.176 64.4438C257.027 64.4438 258.803 65.1773 260.115 66.4836C261.426 67.7899 262.167 69.5626 262.175 71.4138Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-9\" d=\"M117.518 20.4814C117.518 24.5323 118.72 28.4922 120.97 31.8603C123.221 35.2285 126.419 37.8536 130.162 39.4038C133.904 40.954 138.022 41.3596 141.995 40.5693C145.968 39.779 149.618 37.8284 152.482 34.964C155.347 32.0996 157.297 28.4502 158.088 24.4772C158.878 20.5042 158.472 16.386 156.922 12.6435C155.372 8.90104 152.747 5.70227 149.379 3.45174C146.01 1.20122 142.051 0 138 0C132.568 0 127.358 2.15786 123.517 5.99887C119.676 9.83989 117.518 15.0494 117.518 20.4814Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-10\" d=\"M68.8997 29.4507C68.8997 32.2756 69.7373 35.037 71.3067 37.3858C72.8761 39.7346 75.1068 41.5652 77.7166 42.6462C80.3264 43.7273 83.1982 44.0101 85.9688 43.459C88.7393 42.9079 91.2843 41.5476 93.2818 39.5501C95.2792 37.5526 96.6395 35.0077 97.1906 32.2371C97.7417 29.4665 97.4589 26.5948 96.3779 23.9849C95.2968 21.3751 93.4662 19.1445 91.1174 17.575C88.7686 16.0056 86.0072 15.168 83.1824 15.168C79.3944 15.168 75.7615 16.6728 73.083 19.3513C70.4044 22.0298 68.8997 25.6627 68.8997 29.4507Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-11\" d=\"M88.2671 76.212C88.2615 78.2019 88.8464 80.1488 89.9478 81.8061C91.0492 83.4634 92.6176 84.7566 94.4545 85.522C96.2913 86.2874 98.3139 86.4907 100.266 86.1059C102.219 85.7212 104.013 84.7658 105.422 83.3607C106.831 81.9556 107.792 80.164 108.182 78.2128C108.572 76.2615 108.375 74.2383 107.615 72.3993C106.854 70.5603 105.566 68.9883 103.911 67.8821C102.257 66.776 100.312 66.1856 98.3222 66.1855C95.6604 66.1855 93.1071 67.241 91.2223 69.1205C89.3374 71 88.2747 73.5502 88.2671 76.212Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-12\" d=\"M34.7354 49.1612C34.7297 51.1511 35.3147 53.098 36.4161 54.7553C37.5175 56.4126 39.0859 57.7058 40.9227 58.4712C42.7595 59.2367 44.7822 59.4399 46.7345 59.0551C48.6869 58.6704 50.4812 57.715 51.8902 56.3099C53.2993 54.9048 54.2598 53.1132 54.6501 51.162C55.0404 49.2107 54.843 47.1875 54.0828 45.3485C53.3226 43.5096 52.0338 41.9375 50.3797 40.8313C48.7255 39.7252 46.7803 39.1348 44.7904 39.1348C42.1286 39.1348 39.5754 40.1902 37.6905 42.0697C35.8057 43.9492 34.743 46.4994 34.7354 49.1612Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-13\" d=\"M101.893 112.177C101.893 113.555 102.302 114.903 103.068 116.049C103.834 117.195 104.922 118.088 106.196 118.616C107.47 119.143 108.871 119.281 110.223 119.013C111.575 118.744 112.817 118.08 113.792 117.105C114.767 116.13 115.43 114.888 115.699 113.536C115.968 112.184 115.83 110.783 115.303 109.509C114.775 108.236 113.882 107.147 112.736 106.381C111.589 105.615 110.242 105.207 108.863 105.207C107.017 105.214 105.249 105.951 103.943 107.256C102.638 108.562 101.901 110.33 101.893 112.177Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-14\" d=\"M59.616 91.0369C59.616 92.4154 60.0247 93.763 60.7906 94.9092C61.5565 96.0554 62.6451 96.9487 63.9187 97.4763C65.1923 98.0038 66.5937 98.1418 67.9457 97.8729C69.2977 97.604 70.5397 96.9401 71.5145 95.9654C72.4892 94.9906 73.153 93.7487 73.422 92.3966C73.6909 91.0446 73.5529 89.6432 73.0253 88.3696C72.4978 87.096 71.6045 86.0074 70.4583 85.2415C69.3121 84.4757 67.9645 84.0669 66.5859 84.0669C64.7374 84.0669 62.9646 84.8012 61.6574 86.1083C60.3503 87.4155 59.616 89.1883 59.616 91.0369Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-15\" d=\"M80.4409 122.832C80.4409 123.805 80.7298 124.756 81.271 125.564C81.8121 126.373 82.5812 127.003 83.4806 127.374C84.38 127.745 85.3694 127.84 86.3232 127.648C87.2771 127.457 88.1525 126.986 88.8385 126.296C89.5244 125.606 89.9901 124.728 90.1765 123.773C90.3628 122.818 90.2614 121.829 89.8852 120.932C89.5089 120.034 88.8747 119.269 88.063 118.733C87.2512 118.196 86.2985 117.913 85.3256 117.919C84.0275 117.926 82.7851 118.447 81.8699 119.368C80.9546 120.288 80.4409 121.534 80.4409 122.832Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-16\" d=\"M41.4766 109.006C41.4766 109.977 41.7647 110.927 42.3046 111.735C42.8445 112.543 43.6119 113.173 44.5096 113.545C45.4074 113.917 46.3953 114.014 47.3483 113.824C48.3014 113.635 49.1769 113.167 49.864 112.48C50.5512 111.793 51.0191 110.917 51.2086 109.964C51.3982 109.011 51.301 108.023 50.9291 107.125C50.5572 106.228 49.9274 105.46 49.1195 104.92C48.3115 104.38 47.3616 104.092 46.3898 104.092C45.0867 104.092 43.8371 104.61 42.9156 105.531C41.9942 106.453 41.4766 107.702 41.4766 109.006Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-17\" d=\"M0 92.8093C0 93.781 0.288155 94.7309 0.828032 95.5389C1.36791 96.3469 2.13525 96.9766 3.03304 97.3485C3.93082 97.7204 4.91872 97.8177 5.8718 97.6281C6.82488 97.4385 7.70032 96.9706 8.38745 96.2835C9.07459 95.5963 9.54255 94.7209 9.73213 93.7678C9.92171 92.8147 9.82439 91.8268 9.45251 90.929C9.08064 90.0313 8.45092 89.2639 7.64294 88.724C6.83495 88.1842 5.88502 87.896 4.91327 87.896C3.61019 87.896 2.36046 88.4136 1.43904 89.3351C0.517625 90.2565 0 91.5062 0 92.8093Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-18\" d=\"M13.855 71.4138C13.855 72.7923 14.2638 74.1399 15.0297 75.2861C15.7955 76.4323 16.8841 77.3257 18.1576 77.8532C19.4312 78.3808 20.8327 78.5188 22.1847 78.2499C23.5368 77.9809 24.7787 77.3171 25.7534 76.3423C26.7282 75.3676 27.392 74.1256 27.6609 72.7736C27.9299 71.4216 27.7919 70.0201 27.2643 68.7465C26.7368 67.4729 25.8434 66.3844 24.6972 65.6185C23.551 64.8526 22.2034 64.4438 20.8249 64.4438C18.9764 64.4438 17.2035 65.1782 15.8964 66.4853C14.5893 67.7924 13.855 69.5653 13.855 71.4138Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-19\" d=\"M123.66 69.5845C123.66 72.4093 124.498 75.1708 126.067 77.5196C127.637 79.8683 129.867 81.699 132.477 82.78C135.087 83.861 137.959 84.1439 140.729 83.5928C143.5 83.0417 146.045 81.6814 148.042 79.6839C150.04 77.6864 151.4 75.1415 151.951 72.3709C152.502 69.6003 152.219 66.7286 151.138 64.1187C150.057 61.5089 148.227 59.2782 145.878 57.7088C143.529 56.1394 140.768 55.3018 137.943 55.3018C134.155 55.3018 130.522 56.8065 127.843 59.4851C125.165 62.1636 123.66 65.7965 123.66 69.5845Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-20\" d=\"M127.916 107.206C127.916 109.201 128.508 111.15 129.616 112.808C130.724 114.467 132.298 115.759 134.141 116.522C135.984 117.285 138.011 117.485 139.967 117.096C141.923 116.707 143.72 115.747 145.13 114.336C146.54 112.926 147.501 111.129 147.89 109.173C148.279 107.217 148.079 105.19 147.316 103.347C146.553 101.505 145.26 99.93 143.602 98.822C141.944 97.714 139.994 97.1226 138 97.1226C135.326 97.1226 132.761 98.1849 130.87 100.076C128.979 101.967 127.916 104.532 127.916 107.206Z\" fill=\"#F47B20\"\/>\n    <\/svg>\n<\/div>\n                    <\/div>\n                            <\/div>\n        <\/div>\n\n\n\n    <\/div>\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-white context-white --previous-regular\"><div class=\"container\">\n    <div class=\"excerptCardBlok context-white\">\n\n        <div class=\"excerptCardBlok__container text-center\">\n\n                            <div class=\"excerptCardBlok__title\"><p>Publi\u00e9 dans la revue <em>Respiratory Research<\/em>, f\u00e9vrier 2021<sup>21<\/sup><\/p>\n<\/div>\n            \n                            <div class=\"excerptCardBlok__content\">\n                    <p>\u00ab La DCP chez les patients atteints de BPCO a d\u00e9montr\u00e9 un profil de s\u00e9curit\u00e9 favorable jusqu\u2019\u00e0 3 ans, sans \u00e9v\u00e9nement ind\u00e9sirable grave sur le long terme li\u00e9 au traitement par d\u00e9nervation. Les patients trait\u00e9s par DCP ont pr\u00e9sent\u00e9 une stabilit\u00e9 clinique de leur fonction pulmonaire, de la qualit\u00e9 de vie et des exacerbations sur les 3 ans de suivi. \u00bb<\/p>\n                <\/div>\n            \n                            <div class=\"mt-16\">\n                        <a class=\"btn btn--link\" href=\"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01664-5\" target=\"_blank\">\n        Consultez le rapport complet <i class=\"far fa-arrow-right\"><\/i>\n    <\/a>\n                    <\/div>\n            \n\n        <\/div>\n\n    <\/div>\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-small --bg-white context-white --previous-regular\"><div class=\"container\">\n            <h3 class=\"h-4 | mb-32\">R\u00e9sultats : Stabilit\u00e9 clinique observ\u00e9e apr\u00e8s trois ans<sup>21,22<\/sup><\/h3>\n        <div class=\"iconGridBlok iconGridBlok--small iconGridBlok--4cols\">\n\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-smile-beam\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Qualit\u00e9 de vie stable <\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-balance-scale\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Fonction pulmonaire stable <\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-lungs\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Profil de s\u00e9curit\u00e9 favorable \u00e0 long terme<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n        \n    <\/div>\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n\n<div class=\"horizontal-line\">\n    <hr \/>\n<\/div>\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-small --space-bot-regular --bg-white context-white --previous-small\">\n<div class=\"container\">\n    \n    <div class=\"collapsableGridBlok\">\n        \n        <h3 class=\"collapsableGridBlok__title | h-4\">\n            D\u00e9tails de l\u2019\u00e9tude AIRFLOW-1         <\/h3>\n\n        <div class=\"collapsableGridBlok__content\">\n\n            <div class=\"collapsableGridBlok__layout\">\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Design de l\u2019\u00e9tude<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Etude de dose et de s\u00e9curit\u00e9, multicentrique internationale. <br \/>\r\nRandomisation (N=30) puis confirmation (N=16)<br \/>\r\n <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Population<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Patients diagnostiqu\u00e9s BPCO, symptomatiques, exacerbations mod\u00e9r\u00e9es \u00e0 s\u00e9v\u00e8res <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Investigateurs principaux<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Arschang Valipour, MD, Otto-Wagner Spital (Vienna, Austria)<br \/>\r\nDirk-Jan Slebos, MD, Ph.D., UMCG (Groningen, Netherlands) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Crit\u00e8re d\u2019\u00e9valuation principal<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Taux d\u2019infections respiratoires n\u00e9cessitant une intervention \u00e0 3 mois, et taux et fr\u00e9quence des effets ind\u00e9sirables \u00e0 1 mois, compar\u00e9 au groupe ayant re\u00e7u un dose de 32W (phase confirmation) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Nombre\/Centres<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> N=46<br \/>\r\n10 centres en Europe<br \/>\r\n <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Suivi<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> 3 ans <\/p>\n                    <\/div>\n                            <\/div>\n\n        <\/div>\n\n        \n    <\/div>\n\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-gray context-gray --previous-regular\">\n<div class=\"container\">\n    <div class=\"contentSidebarBlok\">\n\n                    <div class=\"contentSidebarBlok__image | mb-32\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"552\" height=\"206\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-3.png\" class=\"attachment-medium_large size-medium_large\" alt=\"Nuvaira Clinical Development Program - AIRFLOW-3\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-3.png 552w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow-3-300x112.png 300w\" sizes=\"auto, (max-width: 552px) 100vw, 552px\" \/>            <\/div>\n                \n                    <h3 class=\"h-4 mb-24\">Pr\u00e9sentation de l\u2019\u00e9tude<\/h3>\n        \n        <div class=\"contentSidebarBlok__layout\">\n            <div class=\"contentSidebarBlok__main wysiwyg\">\n                <p><strong>EN COURS DE RECRUTEMENT : le premier essai interventionnel majeur visant \u00e0 r\u00e9duire les exacerbations chez les patients atteints de BPCO tr\u00e8s symptomatiques. <\/strong><\/p>\n            <\/div>\n\n            <div class=\"contentSidebarBlok__aside contentSidebarBlok__aside--bubbles\">\n                \n                    <div class=\"c-orange\">\n                        <div class=\"logoDots\">\n    <svg width=\"276\" height=\"128\" viewBox=\"0 0 276 128\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n        <path class=\"path-0\" d=\"M207.1 29.4507C207.1 32.2756 206.262 35.037 204.693 37.3858C203.123 39.7346 200.893 41.5652 198.283 42.6462C195.673 43.7273 192.801 44.0101 190.031 43.459C187.26 42.9079 184.715 41.5476 182.718 39.5501C180.72 37.5526 179.36 35.0077 178.809 32.2371C178.258 29.4665 178.541 26.5948 179.622 23.9849C180.703 21.3751 182.533 19.1445 184.882 17.575C187.231 16.0056 189.992 15.168 192.817 15.168C196.605 15.168 200.238 16.6728 202.917 19.3513C205.595 22.0298 207.1 25.6627 207.1 29.4507Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-1\" d=\"M187.732 76.212C187.738 78.2019 187.153 80.1488 186.051 81.8061C184.95 83.4634 183.381 84.7566 181.545 85.522C179.708 86.2874 177.685 86.4907 175.733 86.1059C173.78 85.7212 171.986 84.7658 170.577 83.3607C169.168 81.9556 168.207 80.164 167.817 78.2128C167.427 76.2615 167.624 74.2383 168.384 72.3993C169.145 70.5603 170.433 68.9883 172.088 67.8821C173.742 66.776 175.687 66.1856 177.677 66.1855C180.339 66.1855 182.892 67.241 184.777 69.1205C186.662 71 187.724 73.5502 187.732 76.212Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-2\" d=\"M241.265 49.1612C241.27 51.1511 240.685 53.098 239.584 54.7553C238.483 56.4126 236.914 57.7058 235.077 58.4712C233.24 59.2367 231.218 59.4399 229.266 59.0551C227.313 58.6704 225.519 57.715 224.11 56.3099C222.701 54.9048 221.74 53.1132 221.35 51.162C220.96 49.2107 221.157 47.1875 221.917 45.3485C222.677 43.5096 223.966 41.9375 225.62 40.8313C227.274 39.7252 229.22 39.1348 231.21 39.1348C233.871 39.1348 236.425 40.1902 238.309 42.0697C240.194 43.9492 241.257 46.4994 241.265 49.1612Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-3\" d=\"M174.107 112.177C174.107 113.555 173.698 114.903 172.932 116.049C172.166 117.195 171.077 118.088 169.804 118.616C168.53 119.143 167.129 119.281 165.777 119.013C164.425 118.744 163.183 118.08 162.208 117.105C161.233 116.13 160.569 114.888 160.3 113.536C160.032 112.184 160.17 110.783 160.697 109.509C161.225 108.236 162.118 107.147 163.264 106.381C164.41 105.615 165.758 105.207 167.137 105.207C168.983 105.214 170.751 105.951 172.057 107.256C173.362 108.562 174.099 110.33 174.107 112.177Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-4\" d=\"M216.384 91.0369C216.384 92.4154 215.975 93.763 215.209 94.9092C214.443 96.0554 213.355 96.9487 212.081 97.4763C210.808 98.0038 209.406 98.1418 208.054 97.8729C206.702 97.604 205.46 96.9401 204.485 95.9654C203.511 94.9906 202.847 93.7487 202.578 92.3966C202.309 91.0446 202.447 89.6432 202.974 88.3696C203.502 87.096 204.395 86.0074 205.542 85.2415C206.688 84.4757 208.035 84.0669 209.414 84.0669C211.262 84.0669 213.035 84.8012 214.342 86.1083C215.65 87.4155 216.384 89.1883 216.384 91.0369Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-5\" d=\"M195.559 122.832C195.559 123.803 195.271 124.753 194.731 125.561C194.191 126.369 193.423 126.999 192.526 127.371C191.628 127.743 190.64 127.84 189.687 127.651C188.734 127.461 187.858 126.993 187.171 126.306C186.484 125.619 186.016 124.743 185.827 123.79C185.637 122.837 185.734 121.849 186.106 120.952C186.478 120.054 187.108 119.286 187.916 118.746C188.724 118.207 189.674 117.918 190.645 117.918C191.949 117.918 193.198 118.436 194.12 119.358C195.041 120.279 195.559 121.529 195.559 122.832Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-6\" d=\"M234.522 109.006C234.522 109.979 234.233 110.93 233.692 111.738C233.151 112.547 232.382 113.177 231.482 113.548C230.583 113.919 229.593 114.014 228.639 113.822C227.686 113.63 226.81 113.16 226.124 112.47C225.438 111.78 224.973 110.901 224.786 109.947C224.6 108.992 224.701 108.003 225.078 107.106C225.454 106.208 226.088 105.443 226.9 104.906C227.711 104.37 228.664 104.087 229.637 104.092C230.935 104.1 232.178 104.621 233.093 105.541C234.008 106.462 234.522 107.707 234.522 109.006Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-7\" d=\"M276 92.8093C276 93.781 275.712 94.7309 275.172 95.5389C274.632 96.3469 273.865 96.9766 272.967 97.3485C272.069 97.7204 271.082 97.8177 270.129 97.6281C269.176 97.4385 268.3 96.9706 267.613 96.2835C266.926 95.5963 266.458 94.7209 266.268 93.7678C266.079 92.8147 266.176 91.8268 266.548 90.929C266.92 90.0313 267.549 89.2639 268.357 88.724C269.165 88.1842 270.115 87.896 271.087 87.896C272.39 87.896 273.64 88.4136 274.561 89.3351C275.483 90.2565 276 91.5062 276 92.8093Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-8\" d=\"M262.175 71.4138C262.18 72.7992 261.775 74.1551 261.009 75.3098C260.243 76.4644 259.152 77.3659 257.874 77.9C256.596 78.434 255.188 78.5767 253.828 78.3099C252.469 78.0431 251.219 77.3788 250.237 76.4012C249.256 75.4236 248.586 74.1766 248.314 72.8183C248.042 71.4599 248.179 70.0513 248.707 68.7708C249.236 67.4903 250.133 66.3956 251.285 65.6253C252.436 64.855 253.791 64.4439 255.176 64.4438C257.027 64.4438 258.803 65.1773 260.115 66.4836C261.426 67.7899 262.167 69.5626 262.175 71.4138Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-9\" d=\"M117.518 20.4814C117.518 24.5323 118.72 28.4922 120.97 31.8603C123.221 35.2285 126.419 37.8536 130.162 39.4038C133.904 40.954 138.022 41.3596 141.995 40.5693C145.968 39.779 149.618 37.8284 152.482 34.964C155.347 32.0996 157.297 28.4502 158.088 24.4772C158.878 20.5042 158.472 16.386 156.922 12.6435C155.372 8.90104 152.747 5.70227 149.379 3.45174C146.01 1.20122 142.051 0 138 0C132.568 0 127.358 2.15786 123.517 5.99887C119.676 9.83989 117.518 15.0494 117.518 20.4814Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-10\" d=\"M68.8997 29.4507C68.8997 32.2756 69.7373 35.037 71.3067 37.3858C72.8761 39.7346 75.1068 41.5652 77.7166 42.6462C80.3264 43.7273 83.1982 44.0101 85.9688 43.459C88.7393 42.9079 91.2843 41.5476 93.2818 39.5501C95.2792 37.5526 96.6395 35.0077 97.1906 32.2371C97.7417 29.4665 97.4589 26.5948 96.3779 23.9849C95.2968 21.3751 93.4662 19.1445 91.1174 17.575C88.7686 16.0056 86.0072 15.168 83.1824 15.168C79.3944 15.168 75.7615 16.6728 73.083 19.3513C70.4044 22.0298 68.8997 25.6627 68.8997 29.4507Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-11\" d=\"M88.2671 76.212C88.2615 78.2019 88.8464 80.1488 89.9478 81.8061C91.0492 83.4634 92.6176 84.7566 94.4545 85.522C96.2913 86.2874 98.3139 86.4907 100.266 86.1059C102.219 85.7212 104.013 84.7658 105.422 83.3607C106.831 81.9556 107.792 80.164 108.182 78.2128C108.572 76.2615 108.375 74.2383 107.615 72.3993C106.854 70.5603 105.566 68.9883 103.911 67.8821C102.257 66.776 100.312 66.1856 98.3222 66.1855C95.6604 66.1855 93.1071 67.241 91.2223 69.1205C89.3374 71 88.2747 73.5502 88.2671 76.212Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-12\" d=\"M34.7354 49.1612C34.7297 51.1511 35.3147 53.098 36.4161 54.7553C37.5175 56.4126 39.0859 57.7058 40.9227 58.4712C42.7595 59.2367 44.7822 59.4399 46.7345 59.0551C48.6869 58.6704 50.4812 57.715 51.8902 56.3099C53.2993 54.9048 54.2598 53.1132 54.6501 51.162C55.0404 49.2107 54.843 47.1875 54.0828 45.3485C53.3226 43.5096 52.0338 41.9375 50.3797 40.8313C48.7255 39.7252 46.7803 39.1348 44.7904 39.1348C42.1286 39.1348 39.5754 40.1902 37.6905 42.0697C35.8057 43.9492 34.743 46.4994 34.7354 49.1612Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-13\" d=\"M101.893 112.177C101.893 113.555 102.302 114.903 103.068 116.049C103.834 117.195 104.922 118.088 106.196 118.616C107.47 119.143 108.871 119.281 110.223 119.013C111.575 118.744 112.817 118.08 113.792 117.105C114.767 116.13 115.43 114.888 115.699 113.536C115.968 112.184 115.83 110.783 115.303 109.509C114.775 108.236 113.882 107.147 112.736 106.381C111.589 105.615 110.242 105.207 108.863 105.207C107.017 105.214 105.249 105.951 103.943 107.256C102.638 108.562 101.901 110.33 101.893 112.177Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-14\" d=\"M59.616 91.0369C59.616 92.4154 60.0247 93.763 60.7906 94.9092C61.5565 96.0554 62.6451 96.9487 63.9187 97.4763C65.1923 98.0038 66.5937 98.1418 67.9457 97.8729C69.2977 97.604 70.5397 96.9401 71.5145 95.9654C72.4892 94.9906 73.153 93.7487 73.422 92.3966C73.6909 91.0446 73.5529 89.6432 73.0253 88.3696C72.4978 87.096 71.6045 86.0074 70.4583 85.2415C69.3121 84.4757 67.9645 84.0669 66.5859 84.0669C64.7374 84.0669 62.9646 84.8012 61.6574 86.1083C60.3503 87.4155 59.616 89.1883 59.616 91.0369Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-15\" d=\"M80.4409 122.832C80.4409 123.805 80.7298 124.756 81.271 125.564C81.8121 126.373 82.5812 127.003 83.4806 127.374C84.38 127.745 85.3694 127.84 86.3232 127.648C87.2771 127.457 88.1525 126.986 88.8385 126.296C89.5244 125.606 89.9901 124.728 90.1765 123.773C90.3628 122.818 90.2614 121.829 89.8852 120.932C89.5089 120.034 88.8747 119.269 88.063 118.733C87.2512 118.196 86.2985 117.913 85.3256 117.919C84.0275 117.926 82.7851 118.447 81.8699 119.368C80.9546 120.288 80.4409 121.534 80.4409 122.832Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-16\" d=\"M41.4766 109.006C41.4766 109.977 41.7647 110.927 42.3046 111.735C42.8445 112.543 43.6119 113.173 44.5096 113.545C45.4074 113.917 46.3953 114.014 47.3483 113.824C48.3014 113.635 49.1769 113.167 49.864 112.48C50.5512 111.793 51.0191 110.917 51.2086 109.964C51.3982 109.011 51.301 108.023 50.9291 107.125C50.5572 106.228 49.9274 105.46 49.1195 104.92C48.3115 104.38 47.3616 104.092 46.3898 104.092C45.0867 104.092 43.8371 104.61 42.9156 105.531C41.9942 106.453 41.4766 107.702 41.4766 109.006Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-17\" d=\"M0 92.8093C0 93.781 0.288155 94.7309 0.828032 95.5389C1.36791 96.3469 2.13525 96.9766 3.03304 97.3485C3.93082 97.7204 4.91872 97.8177 5.8718 97.6281C6.82488 97.4385 7.70032 96.9706 8.38745 96.2835C9.07459 95.5963 9.54255 94.7209 9.73213 93.7678C9.92171 92.8147 9.82439 91.8268 9.45251 90.929C9.08064 90.0313 8.45092 89.2639 7.64294 88.724C6.83495 88.1842 5.88502 87.896 4.91327 87.896C3.61019 87.896 2.36046 88.4136 1.43904 89.3351C0.517625 90.2565 0 91.5062 0 92.8093Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-18\" d=\"M13.855 71.4138C13.855 72.7923 14.2638 74.1399 15.0297 75.2861C15.7955 76.4323 16.8841 77.3257 18.1576 77.8532C19.4312 78.3808 20.8327 78.5188 22.1847 78.2499C23.5368 77.9809 24.7787 77.3171 25.7534 76.3423C26.7282 75.3676 27.392 74.1256 27.6609 72.7736C27.9299 71.4216 27.7919 70.0201 27.2643 68.7465C26.7368 67.4729 25.8434 66.3844 24.6972 65.6185C23.551 64.8526 22.2034 64.4438 20.8249 64.4438C18.9764 64.4438 17.2035 65.1782 15.8964 66.4853C14.5893 67.7924 13.855 69.5653 13.855 71.4138Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-19\" d=\"M123.66 69.5845C123.66 72.4093 124.498 75.1708 126.067 77.5196C127.637 79.8683 129.867 81.699 132.477 82.78C135.087 83.861 137.959 84.1439 140.729 83.5928C143.5 83.0417 146.045 81.6814 148.042 79.6839C150.04 77.6864 151.4 75.1415 151.951 72.3709C152.502 69.6003 152.219 66.7286 151.138 64.1187C150.057 61.5089 148.227 59.2782 145.878 57.7088C143.529 56.1394 140.768 55.3018 137.943 55.3018C134.155 55.3018 130.522 56.8065 127.843 59.4851C125.165 62.1636 123.66 65.7965 123.66 69.5845Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-20\" d=\"M127.916 107.206C127.916 109.201 128.508 111.15 129.616 112.808C130.724 114.467 132.298 115.759 134.141 116.522C135.984 117.285 138.011 117.485 139.967 117.096C141.923 116.707 143.72 115.747 145.13 114.336C146.54 112.926 147.501 111.129 147.89 109.173C148.279 107.217 148.079 105.19 147.316 103.347C146.553 101.505 145.26 99.93 143.602 98.822C141.944 97.714 139.994 97.1226 138 97.1226C135.326 97.1226 132.761 98.1849 130.87 100.076C128.979 101.967 127.916 104.532 127.916 107.206Z\" fill=\"#F47B20\"\/>\n    <\/svg>\n<\/div>\n                    <\/div>\n                            <\/div>\n        <\/div>\n\n\n\n    <\/div>\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n<div class=\"horizontal-line\">\n    <hr \/>\n<\/div>\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-small --space-bot-small --bg-gray context-gray --previous-regular\"><div class=\"container\">\n            <h3 class=\"h-4 | mb-32\">Randomis\u00e9e 1 :1, Double aveugle, Proc\u00e9dure simul\u00e9e, Etude Pivot FDA<\/h3>\n        <div class=\"iconGridBlok iconGridBlok--small iconGridBlok--3cols\">\n\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-abacus\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Objectif principal :<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                    Comparaison de la probabilit\u00e9 des sujets \u00e0 pr\u00e9senter une exacerbation de BPCO mod\u00e9r\u00e9e ou s\u00e9v\u00e8re  entre le groupe de traitement actif et le groupe de traitement simul\u00e9, \u00e0 1 an.                <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-users\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Plus de 400 patients<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n                    <div class=\"iconGridBlok__item\">\n                                    <div class=\"iconGridBlok__icon\">\n                        <i class=\"fad fa-map-marked\"><\/i>\n                    <\/div>\n                \n                <h3 class=\"iconGridBlok__title\">\n                    <strong>Multicentrique (USA, Europe)<\/strong>\n                <\/h3>\n                <div class=\"iconGridBlok__text\">\n                                    <\/div>\n            <\/div>\n        \n    <\/div>\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-gray context-gray --previous-small\">\n<div class=\"container text-left\">\n        <a class=\"btn btn--gradient\" href=\"https:\/\/nuvaira.com\/fr\/resources\/\" >\n        Recherchez un centre participant <i class=\"far fa-arrow-right\"><\/i>\n    <\/a>\n    <\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"horizontal-line\">\n    <hr \/>\n<\/div>\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-small --space-bot-regular --bg-gray context-gray --previous-regular\">\n<div class=\"container\">\n    \n    <div class=\"collapsableGridBlok\">\n        \n        <h3 class=\"collapsableGridBlok__title | h-4\">\n            D\u00e9tails de l\u2019\u00e9tude AIRFLOW-3         <\/h3>\n\n        <div class=\"collapsableGridBlok__content\">\n\n            <div class=\"collapsableGridBlok__layout\">\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Design de l\u2019\u00e9tude<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Etude de sup\u00e9riorit\u00e9, multicentrique internationale, randomis\u00e9e, en double aveugle contre proc\u00e9dure simul\u00e9e (sham).<br \/>\r\nEtude pivot, phase III <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Population<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Patients diagnostiqu\u00e9s BPCO, exacerbations mod\u00e9r\u00e9es \u00e0 s\u00e9v\u00e8res, symptomatiques et \u00e0 risque d\u2019exacerbation de BPCO (GOLD 2\/3, Groupe D) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Investigateurs principaux<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Frank Sciurba, MD, UPMC (Pittsburgh PA USA)<br \/>\r\nDirk-Jan Slebos, MD, Ph.D., UMCG (Groningen Netherlands) <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Crit\u00e8re d\u2019\u00e9valuation principal<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Comparaison du taux d\u2019exacerbation de BPCO mod\u00e9r\u00e9es \u00e0 s\u00e9v\u00e8res (analyse du temps jusqu\u2019\u00e0 le survenue du premier \u00e9v\u00e8nement) entre la DCP+ traitement medical et proc\u00e9dure simul\u00e9e+traitement m\u00e9dical.<br \/>\r\n<br \/>\r\n <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Nombre\/Centres<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> N= plus de 400 (randomisation 1:1)<br \/>\r\n40 centres : 25 US, 15 Europe<br \/>\r\n <\/p>\n                    <\/div>\n                                    <div class=\"collapsableGridBlok__item\">\n                        <h4 class=\"collapsableGridBlok__itemTitle\">Suivi<\/h4>\n                        <p class=\"collapsableGridBlok__itemText\"> Crit\u00e8re principal : 1 an<br \/>\r\nLev\u00e9e d\u2019aveugle avec possibilit\u00e9 de cross over pour les patients du groupe proc\u00e9dure simul\u00e9e : 1 an<br \/>\r\nSuivi annuel jusqu\u2019\u00e0 5 ans<br \/>\r\n <\/p>\n                    <\/div>\n                            <\/div>\n\n        <\/div>\n\n        \n    <\/div>\n\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-white context-white --previous-regular\">\n    <div class=\"container\">\n        <div class=\"sectionHeading sectionHeading--no-ornament  sectionHeading--center\">\n\n            <div class=\"sectionHeading__content\">\n\n                \n                                    <h2 class=\"h-2\">Publications<\/h2>\n                \n                \n            <\/div>\n\n            \n        <\/div>\n    <\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-white context-white --previous-regular\"><div class=\"container\">\n\n    <div class=\"downloadsBlok downloadsBlok--column\">\n\n                    <div class=\"downloadsBlok__item\">\n                <h3 class=\"downloadsBlok__title h-3\">R\u00e9f\u00e9rences bibliographiques sur la D\u00e9nervation Cibl\u00e9e des Poumons<\/h3>\n\n                \n                                    <div class=\"mt-8\">\n                        <a class=\"btn btn--link\" href=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/TLD-Bibliography_Nuvaira_14Oct21.pdf\" target=\"_blank\" download>\n                            T\u00e9l\u00e9chargez le PDF <i class=\"far fa-arrow-to-bottom\"><\/i>\n                        <\/a>\n                    <\/div>\n                            <\/div>\n                    <div class=\"downloadsBlok__item\">\n                <h3 class=\"downloadsBlok__title h-3\">R\u00e9f\u00e9rences bibliographiques sur le m\u00e9canisme d\u2019action de la D\u00e9nervation Cibl\u00e9e des Poumons<\/h3>\n\n                \n                                    <div class=\"mt-8\">\n                        <a class=\"btn btn--link\" href=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/MOA-Bibliography_Nuvaira_June2019.pdf\" target=\"_blank\" download>\n                            T\u00e9l\u00e9chargez le PDF <i class=\"far fa-arrow-to-bottom\"><\/i>\n                        <\/a>\n                    <\/div>\n                            <\/div>\n        \n    <\/div>\n\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n\n<div class=\"jumpToSectionBlok\" id=\"section-airflow-trial\">\n    <\/div>\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-gradient context-purple --previous-regular\">\n<div class=\"ctaBlok c-white\">\n\n    <div class=\"container container--offset-3 | text-center\">\n                    <h2 class=\"h-4\">Les exacerbations de la BPCO sont le probl\u00e8me. <br \/>\r\nContribuez \u00e0 la solution. <\/h2>\n        \n                    <div class=\"mt-16\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"342\" height=\"128\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow3-cta.png\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow3-cta.png 342w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/airflow3-cta-300x112.png 300w\" sizes=\"auto, (max-width: 342px) 100vw, 342px\" \/>            <\/div>\n        \n                    <p class=\"mt-16\">L\u2019essai clinique AIRFLOW-3 est le premier essai interventionnel visant \u00e0 r\u00e9duire le risque d\u2019exacerbations chez les patients atteints de BPCO recevant un traitement pharmaceutique optimal. <\/p>\n        \n                    <div class=\"mt-32\">\n                    <a class=\"btn btn--translucent\" href=\"https:\/\/nuvaira.com\/fr\/patient-selection\/\" >\n        D\u00e9couvrez si votre patient pourrait \u00eatre un candidat <i class=\"far fa-arrow-right\"><\/i>\n    <\/a>\n                <\/div>\n            <\/div>\n\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-868","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Preuves cliniques - Nuvaira<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nuvaira.com\/fr\/clinical-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Preuves cliniques - Nuvaira\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nuvaira.com\/fr\/clinical-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"Nuvaira\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-02T13:39:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/clinical-evidence\\\/\",\"url\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/clinical-evidence\\\/\",\"name\":\"Preuves cliniques - Nuvaira\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-04-26T22:06:16+00:00\",\"dateModified\":\"2022-06-02T13:39:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/clinical-evidence\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nuvaira.com\\\/fr\\\/clinical-evidence\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/clinical-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Preuves cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/\",\"name\":\"Nuvaira\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Preuves cliniques - Nuvaira","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/","og_locale":"fr_FR","og_type":"article","og_title":"Preuves cliniques - Nuvaira","og_url":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/","og_site_name":"Nuvaira","article_modified_time":"2022-06-02T13:39:00+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/","url":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/","name":"Preuves cliniques - Nuvaira","isPartOf":{"@id":"https:\/\/nuvaira.com\/fr\/#website"},"datePublished":"2022-04-26T22:06:16+00:00","dateModified":"2022-06-02T13:39:00+00:00","breadcrumb":{"@id":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nuvaira.com\/fr\/clinical-evidence\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nuvaira.com\/fr\/clinical-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nuvaira.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Preuves cliniques"}]},{"@type":"WebSite","@id":"https:\/\/nuvaira.com\/fr\/#website","url":"https:\/\/nuvaira.com\/fr\/","name":"Nuvaira","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nuvaira.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/pages\/868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/comments?post=868"}],"version-history":[{"count":0,"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/pages\/868\/revisions"}],"wp:attachment":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/media?parent=868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}